Detection of Immunotoxic Gluten Peptides in Feces (CELIQK2)
The purpose of this study is to monitor of gluten-free diet compliance in celiac patients by assessment of gliadin 33-mer equivalent epitopes in feces.
|Study Design:||Observational Model: Cohort
Time Perspective: Retrospective
|Official Title:||Phase 0 Monitoring of Gluten-free Diet Compliance in Celiac Patients by Assessment of Gliadin 33-mer Equivalent Epitopes in Feces|
- Monitoring of gluten-free diet compliance in celiac patients [ Time Frame: April-July 2011 (3 months) ] [ Designated as safety issue: No ]Usual gluten diet for celiac (home diet not modified for this trial)
Biospecimen Retention: Samples Without DNA
|Study Start Date:||April 2011|
|Study Completion Date:||July 2011|
Other: Detection of gluten in feces
Detection of Gluten in Feces
Certain immunotoxic peptides from gluten are resistant to gastrointestinal digestion and can interact with celiac patient factors to trigger immunological response. Gluten-free diet (GFD) is the only effective treatment for celiac disease (CD) and its compliance should be monitored to avoid accumulative damage. However, practical methods to monitor diet compliance and to detect the origin of an outbreak of celiac clinical symptoms are not available.
This study assesses the capacity to determine the gluten ingestion, and to monitor the GFD compliance in celiac patients by detection of gluten and gliadin 33-mer equivalent peptidic epitopes in human feces.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01478867
|Department of Microbiology and Parasitology, Faculty of Pharmacy, University of Seville|
|Seville, Spain, 41012|
|Principal Investigator:||Carolina Sousa, Professor||University of Seville, Spain|